Symbolbild · KI-generiert
ARS Pharmaceuticals, Inc.
Stock factsheet
Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. Market capitalisation is an order of magnitude as of the date shown, not a real-time figure. The size class follows the thresholds in common use (micro < $300m, small < $2bn, mid < $10bn) and is meant as an indication, not a definition.
Company profile
ARS Pharmaceuticals develops medicines for the treatment of allergic emergencies. The company developed Neffy, a nasal epinephrine spray as an alternative to the EpiPen, which received FDA approval in 2024. Its target population is patients with severe allergic shock (anaphylaxis).
Short profile generated automatically and checked for plausibility. A full editorial profile follows once we cover the company.
Share price
Price data from TradingView, possibly delayed. Not investment advice.
Comparable companies
Companies in the Biotech & Pharma sector of a similar size.
| Company | Ticker | Exchange | Market cap |
|---|---|---|---|
| ARS Pharmaceuticals, Inc. | SPRY | NASDAQ | 509 Mio. USD |
| Verastem, Inc. | VSTM | NASDAQ | 510 Mio. USD |
| Zura Bio Limited | ZURA | NASDAQ | 516 Mio. USD |
| Crescent Biopharma, Inc. | CBIO | NASDAQ | 516 Mio. USD |
| Ginkgo Bioworks Holdings, Inc. | DNA | NYSE | 503 Mio. USD |
| REGENXBIO Inc. | RGNX | NASDAQ | 501 Mio. USD |
| Arvinas, Inc. | ARVN | NASDAQ | 518 Mio. USD |
Investor Relations
We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.
Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.